Advanced search
Publication Cover
Acta Cardiologica Volume 73, 2018 - Issue 1
Submit an article Journal homepage
74
Views
2
CrossRef citations to date
0
Altmetric
Original Scientific Papers

Plasma osteopontin concentration is elevated in patients with coronary bare metal stent restenosis

Kerem Can YilmazCardiology Department, Faculty of Medicine, Baskent University, Ankara, TurkeyCorrespondence[email protected]
,
Ugur Abbas BalCardiology Department, Faculty of Medicine, Baskent University, Ankara, Turkey
,
Emir KaracaglarCardiology Department, Faculty of Medicine, Baskent University, Ankara, Turkey
,
Kaan OkyayCardiology Department, Faculty of Medicine, Baskent University, Ankara, Turkey
,
Alp AydinalpCardiology Department, Faculty of Medicine, Baskent University, Ankara, Turkey
,
Aylin YildirirCardiology Department, Faculty of Medicine, Baskent University, Ankara, Turkey
&
Haldun MuderrisogluCardiology Department, Faculty of Medicine, Baskent University, Ankara, Turkey
 show all
Pages 69-74 | Received 16 Sep 2016, Accepted 15 Feb 2017, Published online: 25 Aug 2017

References

  • Rajagopal V, Rockson SG. Coronary restenosis: a review of mechanisms and management. Am J Med. 2003;115:547–553.
  • Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 2007;27:2302–2309.
  • Ohshima S, Yamaguchi N, Nishioka K, et al. Enhanced local production of osteopontin in rheumatoid joints. J Rheumatol. 2002;29:2061–2067.
  • Takemoto M, Yokote K, Nishimura M, et al. Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis. Arterioscler Thromb Vasc Biol. 2000;20:624–628.
  • De Feyter PJ, Foley D. Coronary stent implantation: a panacea for the interventional cardiologist? Eur Heart J. 2000;21:1719–1726.
  • Ikeda T, Shirasawa T, Esaki Y, et al. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest. 1993;92:2814–2820.
  • Giachelli CM, Bae N, Almeida M, et al. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest. 1993;92:1686–1696.
  • Liaw L, Lombardi DM, Almeida MM, et al. Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation. Arterioscler Thromb Vasc Biol. 1997;17:188–193.
  • Gadeau AP, Campan M, Millet D, et al. Osteopontin overexpression is associated with arterial smooth muscle cell proliferation in vitro. Arterioscler Thromb. 1993;13:120–125.
  • Panda D, Kundu GC, Lee BI, et al. Potential roles of osteopontin and alphaVbeta3 integrin in the development of coronary artery restenosis after angioplasty. Proc Natl Acad Sci USA. 1997;94:9308–9313.
  • Morice MC, Serruys PW, Sousa JE, RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–1780.
  • Heinegård D, Hultenby K, Oldberg A, et al. Macromolecules in bone matrix. Connect Tissue Res. 1989;21:3–11.
  • Wexler L, Brundage B, Crouse J, et al. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group. Circulation. 1996;94:1175–1192.
  • Ohmori R, Momiyama Y, Taniguchi H, et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis. 2003;170:333–337.
  • Georgiadou P, Iliodromitis KE, Kolokathis F, et al. Osteopontin as a novel prognostic marker in stable ischaemic heart disease: a 3-year follow-up study. Eur J Clin Invest. 2010;40:288–293.
  • Mohamadpour AH, Abdolrahmani L, Mirzaei H, et al. Serum osteopontin concentrations in relation to coronary artery disease. Arch Med Res. 2015;46:112–117.
  • Minoretti P, Falcone C, Calcagnino M, et al. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J. 2006;27:802–807.
  • Yan X, Sano M, Lu L, et al. Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2010;9:70.
  • Tousoulis D, Siasos G, Maniatis K, et al. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol. 2013;167:1924–1928.
  • Momiyama Y, Ohmori R, Fayad AZ, et al. Associations between plasma osteopontin levels and the severities of coronary and aortic atherosclerosis. Atherosclerosis. 2010;210:668–670.
  • Berezin AE, Kremzer AA. Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease. Atherosclerosis. 2013;229:475–481.
  • Kato R, Momiyama Y, Ohmori R, et al. High plasma levels of osteopontin in patients with restenosis after percutaneous coronary intervention. Arterioscler Thromb Vasc Biol. 2006;26:e1–e2.
  • Kato R, Momiyama Y, Ohmori R, et al. Prognostic significance of plasma osteopontin levels in patients undergoing percutaneous coronary intervention. Circ J. 2009;73:152–157.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Novo Nordisk – Driving change to defeat serious chronic diseases.
Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.